The Long-Term Survi...
 
Notifications
Clear all

The Long-Term Survival of a Patient With Stage IV Renal Cell Carcinoma Following an Integrative Treatment Approach Including the Intravenous α-Lipoic Acid/Low-Dose Naltrexone Protocol

8 Posts
4 Users
0 Likes
2,700 Views
Daniel
(@daniel)
Admin
Joined: 7 years ago
Posts: 1156
Topic starter  

https://journals.sagepub.com/doi/full/10.1177/1534735417747984

In this case report, we describe the treatment of a 64-year-old male patient diagnosed with metastatic renal cell carcinoma (RCC) in June of 2008. In spite of a left nephrectomy and the standard oncological protocols, the patient developed a solitary left lung metastasis that continued to grow. He was informed that given his diagnosis and poor response to conventional therapy, any further treatment would, at best, be palliative. The patient arrived at the Integrative Medical Center of New Mexico in August of 2010. He was in very poor health, weak, and cachectic. An integrative program—developed by one of the authors using intravenous (IV) α-lipoic acid, IV vitamin C, low-dose naltrexone, and hydroxycitrate, and a healthy life style program—was initiated. From August 2010 to August 2015, the patient’s RCC with left lung metastasis was followed closely using computed tomography and positron emission tomography/computed tomography imaging. His most recent positron emission tomography scan demonstrated no residual increased glucose uptake in his left lung. After only a few treatments of IV α-lipoic acid and IV vitamin C, his symptoms began to improve, and the patient regained his baseline weight. His energy and outlook improved, and he returned to work. The patient had stable disease with disappearance of the signs and symptoms of stage IV RCC, a full 9 years following diagnosis, with a gentle integrative program, which is essentially free of side effects. As of November 2017 the patient feels well and is working at his full-time job.


   
Quote
shiningrice
(@shiningrice)
Joined: 3 years ago
Posts: 2
 

My husband has left kidney cancer, boney metastases and abdominal perinoreal area. He never do chemo. I heard people cured their cancer with dewormer. Do you think it is effective against kidney cancer? 


   
ReplyQuote
Daniel
(@daniel)
Admin
Joined: 7 years ago
Posts: 1156
Topic starter  

@shiningrice

Dear,

I am sorry to hear about your husband. Is he planning to do conventional treatments such as chemo or he only accepts alternative treatments?

Please note that on this website the contributors and myself discussed many treatment options that offer evidence-based hope even when the conventional treatment approaches stop working.

Some can be used as stand alone, others can be used together with the conventional treatments to help increase or enable the effectiveness of conventional treatments. Because of the angle we take here to look at cancer (e.g. cell metabolism, hormone modulation, ion dynamics modulation, etc.) most of the treatments discussed here are relevant for most of the cancers, including kidney cancer. Please take the time to read some posts on this website. Even if a post was written 3-years ago it will have the same relevance as if it was written today.

Yes, dewarmers can also be relevant and I would certainly try them.

One that I would consider is Mebendazole https://www.cancertreatmentsresearch.com/the-over-the-counter-drug-mebendazole-acts-like-chemotherapy-but-with-virtually-no-side-effects/

The other is Fenbendazole https://www.cancertreatmentsresearch.com/fenbendazole/

Angiogenesis inhibitors are specifically relevant for kidney cancer as well as peritoneal mets. Here is a list of angiogenesis inhibitors https://www.cancertreatmentsresearch.com/category/angiogenesis-inhibitors/

Kind regards,
Daniel

 


   
ReplyQuote
shiningrice
(@shiningrice)
Joined: 3 years ago
Posts: 2
 

@daniel

He never does Chemo or Radiation. To this point even Conventional Treatment cant effective for him. He is going to do Poly MPV IV.  I will check on those website. Thank you.


   
ReplyQuote
Daniel
(@daniel)
Admin
Joined: 7 years ago
Posts: 1156
Topic starter  

@shiningrice

Dr. Khan at Medicore in Canada said they used DCA successfully in renal cell cancer https://medicorcancer.com/new-dca-publication-world-first/

I discussed DCA here https://www.cancertreatmentsresearch.com/dichloroacetate-dca-treatment-strategy/

I would not loose the time with one treatment only.


   
ReplyQuote
patgarner79@gmail.com
(@patgarner79gmail-com)
Joined: 5 months ago
Posts: 1
 

I was diagnosed with renal-cell carcinoma in 2005. I had my right kidney removed at that time. More small tumors showed up in my pancreas and lungs a few years later. I had some tumors removed from my lungs and pancreas in 2011. I've been taking an oral chemo for the past 10 years (Sutent). Some new tumors have shown up again in my pancreas and left kidney. Has fenbendazole been affective in the treatment of renal cell carcinoma?

Thanks for any information.

Pat Garner


   
ReplyQuote
johan
(@j)
Joined: 4 years ago
Posts: 1190
 

Hi Pat, here's more information on fenbendazole:

 

https://www.cancertreatmentsresearch.com/community/kidney-cancer/drug-repositioning-for-renal-cell-carcinoma/#post-5649

https://www.cancertreatmentsresearch.com/fenbendazole/?highlight=fenbendazole

 

A 63-year-old Caucasian male presented with flank pain, rapid weight loss, and transient fever. Abdominal Computed Topography (CT) revealed a 3 cm left lower-pole solid renal mass. He underwent open partial nephrectomy with pathology showing pT1a highgrade clear cell Renal Cell Carcinoma (RCC). Several months later, he developed persistent left flank pain with finding of a 5.2 cm left kidney mass. Fine Needle Aspiration (FNA) biopsy redemonstrated clear cell RCC, and pazopanib 800 mg was initiated. Follow-up CT revealed a new 1.4 cm pancreatic head/body lesion, persistent left renal mass, and signs of sigmoid colitis. Given the concerns for disease progression and intolerable side effects, pazopanib was discontinued and cabozantinib was initiated. Interval Magnetic Resonance Imaging (MRI) showed stable size of recurrent left renal mass, mild decrease in 2.9 cm pancreatic head lesion, stable 1.2 cm distal pancreatic body lesion, and new 1.1 cm right posterior iliac bone lesion. Cabozantinib was ultimately discontinued due to persistent intolerable side effects. One month after discontinuation, repeat MRI showed increase in size of recurrent left renal mass, mild decrease in 2.3 cm pancreatic head lesion, stable 1.4 cm distal pancreatic body lesion, and unchanged 1.1 cm right posterior iliac bone lesion. Third-line treatment with nivolumab was initiated, and he only received three total treatments (240 mg × 3) over the course of a month due to developing severe rash and colitis. He was treated with steroids with resolution of colitis. During this time, he also started alternative therapy with FBZ 1 gm three times per week at the suggestion of one of his friends with head/neck cancer. Interval MRI imaging found near complete resolution of the previously noted left renal mass as well as decrease in pancreatic head/body and right posterior iliac spine lesions (Figure 1). Serial imaging for the past 10 months have not shown any evidence of recurrence or metastatic disease. He has continued taking FBZ without any reported side effects.
https://www.scitechnol.com/peer-review/fenbendazole-enhancing-antitumor-effect-a-case-series-2Kms.php?article_id=14307


   
ReplyQuote
johan
(@j)
Joined: 4 years ago
Posts: 1190
 
Posted by: @j

Hi Pat, here's more information on fenbendazole:

 

https://www.cancertreatmentsresearch.com/community/kidney-cancer/drug-repositioning-for-renal-cell-carcinoma/#post-5649

https://www.cancertreatmentsresearch.com/fenbendazole/?highlight=fenbendazole

 

A 63-year-old Caucasian male presented with flank pain, rapid weight loss, and transient fever. Abdominal Computed Topography (CT) revealed a 3 cm left lower-pole solid renal mass. He underwent open partial nephrectomy with pathology showing pT1a highgrade clear cell Renal Cell Carcinoma (RCC). Several months later, he developed persistent left flank pain with finding of a 5.2 cm left kidney mass. Fine Needle Aspiration (FNA) biopsy redemonstrated clear cell RCC, and pazopanib 800 mg was initiated. Follow-up CT revealed a new 1.4 cm pancreatic head/body lesion, persistent left renal mass, and signs of sigmoid colitis. Given the concerns for disease progression and intolerable side effects, pazopanib was discontinued and cabozantinib was initiated. Interval Magnetic Resonance Imaging (MRI) showed stable size of recurrent left renal mass, mild decrease in 2.9 cm pancreatic head lesion, stable 1.2 cm distal pancreatic body lesion, and new 1.1 cm right posterior iliac bone lesion. Cabozantinib was ultimately discontinued due to persistent intolerable side effects. One month after discontinuation, repeat MRI showed increase in size of recurrent left renal mass, mild decrease in 2.3 cm pancreatic head lesion, stable 1.4 cm distal pancreatic body lesion, and unchanged 1.1 cm right posterior iliac bone lesion. Third-line treatment with nivolumab was initiated, and he only received three total treatments (240 mg × 3) over the course of a month due to developing severe rash and colitis. He was treated with steroids with resolution of colitis. During this time, he also started alternative therapy with FBZ 1 gm three times per week at the suggestion of one of his friends with head/neck cancer. Interval MRI imaging found near complete resolution of the previously noted left renal mass as well as decrease in pancreatic head/body and right posterior iliac spine lesions (Figure 1). Serial imaging for the past 10 months have not shown any evidence of recurrence or metastatic disease. He has continued taking FBZ without any reported side effects.
https://www.scitechnol.com/peer-review/fenbendazole-enhancing-antitumor-effect-a-case-series-2Kms.php?article_id=14307

@patgarner79gmail-com

 


   
ReplyQuote
Share: